Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice

European Journal of Haematology

Volumn 72, Issue 3, 2004, Pages 166-171

  Rousselot, Philippe ^a,b   Larghero, Jérôme ^a,b   Labaume, Sylvaine ^a   Poupon, Joël ^c   Chopin, Martine ^a   Dosquet, Christine ^a   Marolleau, Jean Pierre ^a   Janin, Anne ^a   Brouet, Jean Claude ^a   Fermand, Jean Paul ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c HÔPITAL FERNAND WIDAL   (France)

Author keywords

Arsenic trioxide; Melarsoprol; Multiple myeloma; Scid mice

Indexed keywords

ARSENIC TRIOXIDE; BIOLOGICAL MARKER; BUFFER; IMMUNOGLOBULIN G; INTERLEUKIN 6 RECEPTOR; MELARSOPROL; PARAPROTEIN; PHOSPHATE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IRRADIATION; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; SERUM; SOLUBILITY; STATISTICAL SIGNIFICANCE;

EID: 10744220474     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00194.x     Document Type: Article

References (17)

1. IMRIE K, ESMAIL R, MEYER RM. Members of the hematology disease site group of the cancer care ontario practice guidelines initiative. The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: a practice guideline of the cancer care ontario practice guidelines initiative. Ann Intern Med 2002; 136:619-629.
2. BARLOGIE B, TRICOT G, ANAISSIE E. Thalidomide in the management of multiple myeloma. Semin Oncol 2001;28:577-582.
3. ROUSSELOT P, LABAUME S, MAROLLEAU JP, LARGHERO J, NOGUERA MH, BROUET JC, FERMAND JP. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041-1048.
4. LABAUME S, CHOPIN M, PLA M, BROUET JC. Differential in vitro and in vivo effects of all-trans retinoic acid on the growth of human myeloma cells. Leuk Lymphoma 1998;30:361-366.
5. RECHER C, CHOPIN M, RAFFOUX E, PIERRON G, POUPON J, SIGAUX F, DOMBRET H, STERN MH. In vitro and in vivo effectiveness of arsenic trioxide against murine T-cell prolymphocytic leukaemia. Br J Haematol 2002;117:343-350.
6. GRILLOT-COURVALIN C, LABAUME S, BROUET JC. Differentiation by IL2 of a subpopulation of human B cells. Scand J Immunol 1986;23:679-684.
7. BROWN D, KOGAN S, LAGASSE E, WEISSMAN I, ALCALAY M, PELICCI PG, ATWATER S, BISHOP JM. A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1997;94:2551-2556.
8. LALLEMAND-BREITENBACH V, GUILLEMIN MC, JANIN A, DANIEL MT, DEGOS L, KOGAN SC, BISHOP JM, de THE H. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 1999;189:1043-1052.
9. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14:431-438.
10. LEBLANC R, CATLEY LP, HIDESHIMA T et al. Proteasome inhibitor PS-341 inhibits human myloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
11. LEE YP, SCHWARZ EM, DAVIES M, JO M, GATES J, ZHANG X, WU J, LIEBERMAN JR. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 2002;62:5564-5570.
12. YACCOBY S, EPSTEIN J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-3582.
13. NIU C, YAN H, YU T et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94:3315-3324.
14. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
15. DALTON WS. Targeting the mitochondria: an exciting new approach to myeloma therapy. Clin Cancer Res 2002; 8:3643-3645.
16. BAHLIS NJ, MCCAFFERTY-GRAD J, JORDAN-MCMURRY I et al. Feasibility and correlates of arsenic trioxide combined ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma. Clin Cancer Res 2002;8:3658-3668.
17. MUNSHI NC, TRICOT G, DESIKAN R, BADROS A, ZANGARI M, TOOR A, MORRIS C, ANAISSIE E, BARLOGIE B. Clinical activity of arsenic trioxide for the treatment of multiple myeloma. Leukemia 2002;16:1835-1837.